Webinar: Precision Medicine and Alzheimer’s Disease: Overcoming Biomarker Testing Barriers for Alzheimer’s Disease Patients

Tuesday, October 03, 2023 | 12pm EDT / 11am CDT / 9am PDT / 5pm BST (UK) / 6pm CEST (EU-Central)

Advances in biomarker testing are revolutionizing strategies for diagnosing and managing neurological disorders and shifting the current treatment paradigm to a more personalized approach. Testing has always played a role in the management of mild cognitive impairment or early-stage Alzheimer’s disease (AD) patients.  With the availability of disease-modifying therapies (DMTs), removing barriers to testing now has become an even more critical need to ensure that all eligible patients are tested to identify those that could benefit from therapy. However, the testing paradigm in AD is a complex one – multiple biomarkers and several different modalities including imaging and clinical lab testing exist.

This expert panel will discuss the current AD biomarker testing landscape including opportunities and some key barriers such as test awareness, availability, and reimbursement. The discussion will also highlight ways to address some of these challenges, including building evidence to demonstrate and communicate the value of testing in the management of AD.

In this webinar, you will :

• Understand the current landscape for MCI and early AD-related biomarker testing in terms of clinical practice, evidence context, and payer coverage and reimbursement.
• Review key barriers to clinical adoption of MCI and early AD-related biomarker testing.
• Understand what steps can be taken to overcome these testing barriers and optimize availability and access to testing.

Register here for this webinar to learn how to identify and overcome challenges in Alzheimer’s disease biomarker testing.